Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
Yang Yu, Min Yu, Yanying Li, Xiaojuan Zhou, Tian Tian, Yijia Du, Zegui Tu, Meijuan Huang
Abstract
BRAF gene has been identified as an oncogenic driver and a potential target in various malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion who achieves partial response to the MAK inhibitor trametinib. We also provide a literature review on targeted therapies for BRAF fusions.
Topics & Concepts
TrametinibCancer researchMEK inhibitorMedicineAdenocarcinomaFusion geneDabrafenibLung cancerOncologyInternal medicineCancerGeneMAPK/ERK pathwayVemurafenibBiologyMelanomaKinaseGeneticsMetastatic melanomaMelanoma and MAPK PathwaysCancer Mechanisms and TherapyLung Cancer Treatments and Mutations